Trial Profile
A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult Patients
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs SAR 439794 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Sanofi
- 15 Mar 2018 New trial record